Global Blood Therapeutics

Global Blood Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics to treat grievous blood-based disorders. The company's primary product candidate is voxelotor, an oral, once-daily therapy that modulates hemoglobin's affinity for oxygen. The company is developing voxelotor for sickle cell disease. The company is also engaged in other research and development activities, all of which are in the pre-clinical phase. The company owns or jointly owns and has licensed rights to its product candidates in the U.S., Europe and other markets.
  • TickerGBT
  • ISINUS37890U1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

Liana Moussatos ...
  • Shveta Dighe

EHA Preview: Top-line Voxelotor Phase 3 HOPE Data at EHA on June 14

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

Liana Moussatos ...
  • Shveta Dighe

EHA Preview: Top-line Voxelotor Phase 3 HOPE Data at EHA on June 14

Liana Moussatos ...
  • Shveta Dighe

Q1; Key Inflection Point: Voxelotor Full Phase 3 Data at EHA in June

Two Directors sold after exercising options/sold/subscribed to 178,000 shares at between 36.550USD and 38.000USD.

Two Directors at Global Blood Therapeutics Inc sold after exercising options/sold/subscribed to 178,000 shares at between 36.550USD and 38.000USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close ...

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ValuEngine Rating and Forecast Report for GBT

ResearchPool Subscriptions

Get the most out of your insights

Get in touch